FDA paus­es RAPT Ther­a­peu­tics’ im­munol­o­gy drug stud­ies af­ter pa­tient ex­pe­ri­ences liv­er fail­ure

The FDA has placed a clin­i­cal hold on two tri­als of RAPT Ther­a­peu­tics’ lead im­munol­o­gy can­di­date, zel­necirnon, the biotech an­nounced Tues­day morn­ing.

A pa­tient in a mid-stage atopic der­mati­tis study ex­pe­ri­enced liv­er fail­ure. While the cause is “cur­rent­ly un­known,” the event was deemed “po­ten­tial­ly re­lat­ed to zel­necirnon,” the com­pa­ny said. The pa­tient has since re­ceived a liv­er trans­plant and has re­cov­ered, ac­cord­ing to RAPT ex­ec­u­tives on a Tues­day morn­ing an­a­lyst call.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER